Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. This strategic move comes as the company prepares to expand its contract development and manufacturing organization (CDMO) platform through the upcoming acquisition of Recipharm Israel, a transaction expected to close in the first quarter of 2026.
Kuratz brings over 30 years of leadership experience in supply chain and operations across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee critical functions including procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. His expertise is expected to be instrumental in integrating the new Yavne facility with Scinai's existing Jerusalem operations, thereby enhancing the company's end-to-end CDMO capabilities.
The appointment underscores Scinai's commitment to strengthening its operational infrastructure to support its growing CDMO business. The expanded platform, once the acquisition is completed, will offer a comprehensive suite of services, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient (API) development and synthesis, analytical-method development, and GMP manufacturing. These capabilities position Scinai to serve a broader range of biotechnology and pharmaceutical clients, particularly those seeking a single partner for complex development and manufacturing needs.
According to the company, Kuratz's deep understanding of supply chain dynamics and business process optimization will be crucial as Scinai scales its operations and integrates the new site. His leadership is expected to drive efficiencies, ensure regulatory compliance, and maintain the high standards of quality that clients expect from a GMP-focused CDMO.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies, with a pipeline of candidates licensed from the Max Planck Society and PinCell S.r.l. The company also operates Scinai Biopharma Services Ltd., which provides development and manufacturing services to the biotech and pharma industry through its facilities in Jerusalem and Yavne, Israel. For more information, visit the company's newsroom at https://ibn.fm/SCNI.
